[en] The introduction of basic treatment for heart failure dates to the late 1990s. Since that time, apart from a few new developments reserved for selected patients, there has been little progress. During these years, the epidemiology of the disease has evolved. The number of patients is constantly increasing and the prognosis is often darker than most oncological pathologies. With the arrival of the sacubitril/valsartan combination, Entresto®, a new therapeutic class has emerged. It has shown a significant reduction in mortality and hospitalizations for heart failure. The additional benefits to be expected from this molecule are still being evaluated. Significant positive remodeling seems to be a reality for many patients. This spectacular advance, however, is not the final solution. In addition, patients with preserved heart failure do not seem to benefit the same from this molecule. Other advances are being assessed. Sacubitril/valsartan is the first revolution, perhaps, in a long series.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
NGUYEN TRUNG, Mai-Linh ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Tridetti, J; Service de Cardiologie, CHU Liège, Belgique.
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Language :
French
Title :
Révolution thérapeutique dans l’insuffisance cardiaque.
Alternative titles :
[en] Therapeutic revolution in heart failure.
Publication date :
May 2020
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Be
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet Lond Engl 1999;353:9-13.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
Ancion A, D'Orio V, Lancellotti P. European Society of Cardiology guidelines for the management of chronic heart failure. Rev Med Liege 2017;72:68-73.
Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet Lond Engl 2003;362:772-6.
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet Lond Engl 2010;376:875-85.
Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547-56.
Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics 2007 Update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007;115:e69-171.
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7-11.
Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med 2009;360:1418-28.
Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008;168:418-24.
Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail 2017;19:1095-104.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13:643-52.
Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2014;2:663-70.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-48.
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:1169-86.
de Diego C, Gonzalez-Torres L, Nunez JM, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm 2018;15:395-402.
Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 2019;139:1354-65.
Ancion A, Tridetti J, Nguyen Trung M-L, et al. A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril. Cardiol Ther 2019;8:179-91.
Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95.
Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-20.
Tridetti J, Nguyen Trung ML, et al. The PARAGON-HF trial. Rev Med Liege 2020;75:130-5.
Zinman B, Wanner C, Lachin JM, et al, Empa-Reg Outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Scheen AJ, Paquot N. Une révolution dans le traitement du diabète de type 2: des antidiabétiques dotés d'une protection cardio-rénale indépendamment du contrôle glycémique ! Rev Med Liege 2020;75:392-8.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
Psotka MA, Gottlieb SS, Francis GS, et al. Cardiac calcitropes, myotropes, and mitotropes. J Am Coll Cardiol 2019;73:2345-53.
Teerlink JR, Felker GM, McMurray JJV, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet Lond Engl 2016;388:2895-903.
Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail 2020;8:329-40.
